论文部分内容阅读
在Vertex/Tibtec公司的蛋白酶抑制剂telaprevir的第3个(也是最后1个)Ⅲ期临床试验中,该药已达到有效治疗丙型肝炎(HCV)1型患者的预期指标,该项名为REALIZE的研究的结果支持了前期在未经治疗的丙肝患者中进行的两项关键性试验得出的疗效结论。REALIZE试验有662名经其他药物治疗?
In the third (and last) Phase III trial of Vertex / Tibtec’s protease inhibitor telaprevir, the drug has reached the expected target for effective treatment of patients with hepatitis type 1 (HCV) type 1, REALIZE The results of the study support the conclusion drawn from two pivotal trials conducted in untreated patients with hepatitis C. There are 662 REALIZE trials by other drugs?